Theriva Biologics Inc.
$ 0.26
-9.66%
05 Jun - close price
- Market Cap 13,217,100 USD
- Current Price $ 0.26
- High / Low $ 0.28 / 0.24
- Stock P/E N/A
- Book Value 0.43
- EPS -0.58
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -1.39 %
- 52 Week High 0.86
- 52 Week Low 0.16
About
Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$2.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-12 | 2025-11-12 | 2025-08-11 | 2025-05-14 | 2025-03-06 | 2024-11-12 | 2024-08-13 | 2024-05-07 | 2024-03-25 | 2023-11-13 | 2023-08-08 |
| Reported EPS | -0.05 | -0.0982 | -0.45 | -1.93 | -1.55 | -11.49 | -6.8107 | -10.75 | -0.3 | -0.34 | -0.19 | -0.34 |
| Estimated EPS | -0.05 | -0.37 | -1.13 | -1.08 | -1.56 | -7.22 | -5.25 | -0.28 | -0.34 | -0.41 | -0.37 | -0.36 |
| Surprise | 0 | 0.2718 | 0.68 | -0.85 | 0.01 | -4.27 | -1.5607 | -10.47 | 0.04 | 0.07 | 0.18 | 0.02 |
| Surprise Percentage | 0% | 73.4595% | 60.177% | -78.7037% | 0.641% | -59.1413% | -29.7276% | -3739.2857% | 11.7647% | 17.0732% | 48.6486% | 5.5556% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TOVX
2026-06-05 20:05:44
Theriva Biologics (NYSE: TOVX) was unable to convene its Special Meeting of Stockholders on June 5, 2026, due to a lack of quorum. The meeting was intended to seek approval for the issuance of up to 16,184,560 shares of common stock related to an October 16, 2025 inducement agreement. The company plans to call a new meeting and will be required to hold subsequent meetings every 60 days until the approval is obtained or the warrants are no longer outstanding, unless waived by investors.
2026-05-31 08:39:32
This article provides details about Theriva Biologics, Inc. (AMEX:TOVX), specifically focusing on its number of shareholders. It indicates that further data regarding shareholder numbers, period, value, changes, and change percentages can be found within the platform. The content primarily serves as a placeholder for financial data provided by ICE Data Services and FactSet.
2026-05-08 16:09:30
StockTitan provides a comprehensive resource for THERIVA BIOLOGICS INC (TOVX) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-powered summaries. The platform highlights recent filings such as an 8-K report on June 25, 2025, and details two at-the-market offerings from June 20, 2025, for up to $2.53 million in common stock to fund its oncology pipeline. These filings offer transparency into the company's financial strategies and clinical developments for therapies like VCN-01.
2026-05-07 17:39:50
Maxim Group has reiterated its Buy rating for Theriva Biologics (TOVX.US) and maintained its target price at $1. This indicates a continued positive outlook from the analyst firm regarding the company's prospects.
2026-05-06 20:39:14
Theriva Biologics (NYSEAM:TOVX) is forecast to remain unprofitable for the next three years, with revenue and earnings expected to decline. The company's stock has high volatility, and there are concerns regarding its cash runway, shareholder dilution, and small market capitalization. Despite these risks, the company has announced positive outcomes from clinical trials for its VCN-01 and SYN-004 candidates, with a recent price target increase to US$1.63 by one analyst.
2026-05-06 08:10:32
Theriva Biologics, Inc. reported its first-quarter 2026 results, showing a license revenue of $300K, a significant improvement from a loss in the prior year. The net loss attributable to common stockholders was ($2.04M) and diluted loss per share was ($0.05), both substantial improvements compared to the previous year. The company's business highlights include a shifted pipeline focus to oncology with lead candidate VCN-01 advancing, successful Phase 2b endpoints for VIRAGE, and the out-licensing of SYN-020 for an upfront payment and potential milestones.
